Company Encyclopedia
View More
name
Medicinova
MNOV.US
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001.
1.945 T
MNOV.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking286/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-24.26%E
    • Profit Margin-4656.65%E
    • Gross Margin6.53%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-16.67%D
    • Total Assets YoY-18.14%E
    • Net Assets YoY-20.16%E
  • Cash ScoreD
    • Cash Flow Margin-2.15%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio7.60%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average - Should You Sell?

    MediciNova's stock (NASDAQ:MNOV) recently surpassed its 200-day moving average, trading as high as $1.4570. Analysts have mixed ratings: D. Boral Capital rates it a "buy" with a $9.00 target, Weiss Ratings suggests "sell (d-)", and Zacks Research upgraded it to "hold". The stock has a market cap of $69.16 million and a P/E ratio of -5.64. Institutional investors, including Citadel Advisors LLC, have shown interest, owning 9.90% of the stock. MediciNova focuses on developing treatments for serious diseases with unmet needs.

    Market Beat·
    US
    MNOV
    +0.97%
    Market Beat·
    US
    MNOV
    +0.97%

    MediciNova Reveals MN-001 Metabolite Boosts Cholesterol Efflux in Macrophages

    MediciNova Inc. announced that its drug candidate MN-001's metabolite, MN-002, enhances cholesterol efflux in macrophages, potentially reducing atherosclerosis risk. The findings, published in the Journal of Atherosclerosis and Thrombosis, validate previous clinical studies. MediciNova has completed Phase 2 trial enrollment for MN-001 in hypertriglyceridemia and NAFLD patients, with results expected by summer 2026.

    Reuters·
    US
    MNOV
    +0.97%
    Reuters·
    US
    MNOV
    +0.97%

    Message from the CEO to MediciNova Shareholders | MNOV Stock News

    MediciNova's CEO, Yuichi Iwaki, announced a significant milestone for MN-001, highlighting its novel mechanism in enhancing cholesterol efflux, crucial for treating metabolic disorders. The Phase 2 trial for MN-001 in hypertriglyceridemia and NAFLD due to T2DM is underway, with results expected by summer 2026. MediciNova aims to advance MN-001 as a first-in-class therapy for metabolic and cardiovascular diseases, emphasizing its multi-modal activity and potential clinical outcomes.

    StockTitan·
    US
    MNOV
    +0.97%
    StockTitan·
    US
    MNOV
    +0.97%

    MediciNova Appoints Dr. Christopher Breder as Clinical and Regulatory Advisor

    MediciNova Inc. has appointed Dr. Christopher D. Breder as Clinical and Regulatory Advisor. He will provide strategic guidance for the company’s drug development programs and lead the Scientific Advisory Board upon its formation.

    Reuters·
    US
    MNOV
    +0.97%
    Reuters·
    US
    MNOV
    +0.97%

    Medicinova | 10-Q: FY2025 Q3 Revenue: USD 123.32 K

    LB filings·
    US
    MNOV
    +0.97%
    LB filings·
    US
    MNOV
    +0.97%
    © 2025 Longbridge｜Disclaimer